Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…
TNF-alpha inhibitors (e.g., Remicade, Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’s Entyvio, a CAM…
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’…
Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. Historically, treatment of pediatric CD would begin with safe, albeit often less-…
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…